Biotech Firm Monopar Gains Momentum on Revived Drug Program
Published on 10/10/2025 at 03:18 | Redaktion boerse-global.de
A bold strategic decision has positioned Monopar Therapeutics at the center of investor attention. The clinical-stage biopharmaceutical company is advancing a treatment for Wilson’s disease—a program previously abandoned by pharmaceutical giant AstraZeneca. This development follows the discovery of a computational error in the original study data, identified by one of the drug’s co-discoverers.
Monopar’s commitment to the compound, known as ALXN1840, demonstrates significant confidence in its therapeutic potential despite its rejection by a major industry player. The company stands to benefit from substantial prior research, including completed clinical work, potentially accelerating the drug’s path to regulatory approval and commercialization.
Supporting this renewed development effort, Monopar successfully completed an equity offering in late September, raising gross... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
